Literature DB >> 8550206

Variation of Brucella abortus 2308 infection in BALB/c mice induced by prior vaccination with salt-extractable periplasmic proteins from Brucella abortus 19.

G W Pugh1, L B Tabatabai.   

Abstract

The study compared the immune and protective responses induced in BALB/c mice vaccinated with six salt-extractable periplasmic protein fractions (Brucella cell surface proteins [BCSP]) of Brucella abortus 19 and later challenge exposed with B. abortus 2308. BCSP70 was precipitated with ammonium sulfate at 70% saturation, and BCSP100 was precipitated with ammonium sulfate at 100% saturation by use of supernatant fluid of BCSP70 that had been precipitated with 70% ammonium sulfate. Four subfractions were separated from BCSP100 by anion-exchange high-performance liquid chromatography (HPLC). Monophosphoryl lipid A (MPL) from Salmonella typhimurium Re mutant strain was used as a potential immune response modifier in some vaccines. Reduced or increased numbers of CFU and increased spleen size in the principal groups of mice relative to that of the nonvaccinated control group were considered protectiveness or virulence (survival) criteria. Results indicated that vaccines prepared from BCSP70 and BCSP100 were moderately protective and immunogenic. The subfractions designated BCSP100-A through BCSP100-D purified by anion-exchange HPLC were not protective when MPL was not used as an immune response modifier. However, two subfractions were associated with significant (P < 0.05) increases in CFU per spleen and splenomegaly in vaccinated mice compared with those in nonvaccinated challenge-exposed mice. MPL enhanced protection or was neutral when used with BCSP70, BCSP100, BCSP100-C, and BCSP100-D. Serologic results of an enzyme-linked immunosorbent assay indicated that MPL modulated the immunoglobulin G responses induced by BCSP70, BCSP100, and subfraction BCSP100-B vaccines only. The overall results suggest that certain proteinaceous periplasmic fractions might serve as virulence or survival factors in B. abortus infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550206      PMCID: PMC173800          DOI: 10.1128/iai.64.2.548-556.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

Review 1.  Suppression of the immune response by microorganisms.

Authors:  J H Schwab
Journal:  Bacteriol Rev       Date:  1975-06

2.  Resistance against a subcutaneous Brucella challenge of mice immunized with living or dead Brucella or by transfer of immune serum.

Authors:  P Pardon
Journal:  Ann Immunol (Paris)       Date:  1977 Nov-Dec

3.  Immunity to Brucella in mice vaccinated with a fraction (F8) or a killed vaccine (H38) with or without adjuvant. Level and duration of immunity in relation to dose of vaccine, recall injection and age of mice.

Authors:  N Bosseray
Journal:  Br J Exp Pathol       Date:  1978-08

4.  Isolation and characterization of toxic fractions from Brucella abortus.

Authors:  L B Tabatabai; B L Deyoe; A E Ritchie
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

5.  Specific enzyme-linked immunosorbent assay for detection of bovine antibody to Brucella abortus.

Authors:  L B Tabatabai; B L Deyoe
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

6.  Induction of immune and adjuvant immunoglobulin G responses in mice by Brucella lipopolysaccharide.

Authors:  E Moreno; R S Kurtz; D T Berman
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

7.  Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications.

Authors:  M R Loeb; D H Smith
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

8.  Studies on the immune protection to murine experimental brucellosis conferred by Brucella fractions. I. Positive role of immune serum.

Authors:  S Bascoul; A Cannat; M F Huguet; A Serre
Journal:  Immunology       Date:  1978-08       Impact factor: 7.397

9.  Bovine veneral vibriosis: antigenic variation of the bacterium during infection.

Authors:  L B Corbeil; G G Schurig; P J Bier; A J Winter
Journal:  Infect Immun       Date:  1975-02       Impact factor: 3.441

10.  Pathogenesis and cellular immunity in experimental murine brucellosis.

Authors:  C Cheers
Journal:  Dev Biol Stand       Date:  1984
View more
  2 in total

1.  Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51.

Authors:  M G Stevens; S C Olsen; M V Palmer; G W Pugh
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 2.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.